Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions - PubMed (original) (raw)

. 1999 Aug-Sep;125(8-9):453-60.

doi: 10.1007/s004320050302.

Affiliations

• PMID: 10480337
• DOI: 10.1007/s004320050302

Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions

C Bachor et al. J Cancer Res Clin Oncol. 1999 Aug-Sep.

Abstract

Telomerase is a ribonucleoprotein complex which, by de novo synthesized telomeric TTAGGG repeats, prevents telomere erosion. While telomerase is active in most cancers, conflicting results exist for normal tissues and premalignant lesions. To establish the telomerase status of normal gastrointestinal mucosa and to elucidate whether telomerase up-regulation is an early or late event in carcinogenesis, we determined the telomerase activity of 88 biopsies of normal mucosa from esophagus, stomach, and intestine and compared it with that of 21 samples of premalignant lesions and 6 adenocarcinomas using the telomere-repeat amplification protocol assay. Telomerase was found in all normal tissues, revealing most activity in esophagus (11 samples), followed by intestine (45 samples), and stomach (32 samples). In 53% of the stomach samples, enzyme activity could only be demonstrated when telomerase inhibitors were eliminated by a modified telomerase assay. In the 21 precancerous lesions (5 Barrett's esophagus, 3 stomach intestinal metaplasias, and 13 colorectal adenomas of type I/II dysplasia) a similar or even reduced telomerase activity was seen, while the adenocarcinomas showed high activity. These data demonstrate that telomerase activity is expressed in all epithelia along the gastrointestinal tract, thus confirming our previous hypothesis that telomerase is constitutively expressed in permanently renewing epithelia. Furthermore, activity was not increased in preneoplastic lesions, suggesting that telomerase up-regulation is a late event during carcinogenesis of the esophagus, stomach, and intestine.

PubMed Disclaimer

Similar articles

• Telomere length and telomerase activity in carcinogenesis of the stomach.
  Maruyama Y, Hanai H, Fujita M, Kaneko E. Maruyama Y, et al. Jpn J Clin Oncol. 1997 Aug;27(4):216-20. doi: 10.1093/jjco/27.4.216. Jpn J Clin Oncol. 1997. PMID: 9379506
• Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus.
  Going JJ, Fletcher-Monaghan AJ, Neilson L, Wisman BA, van der Zee A, Stuart RC, Keith WN. Going JJ, et al. Neoplasia. 2004 Jan-Feb;6(1):85-92. Neoplasia. 2004. PMID: 15068673 Free PMC article.
• Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
  Engelhardt M, Drullinsky P, Guillem J, Moore MA. Engelhardt M, et al. Clin Cancer Res. 1997 Nov;3(11):1931-41. Clin Cancer Res. 1997. PMID: 9815582
• Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again.
  Forsyth NR, Wright WE, Shay JW. Forsyth NR, et al. Differentiation. 2002 Jan;69(4-5):188-97. doi: 10.1046/j.1432-0436.2002.690412.x. Differentiation. 2002. PMID: 11841477 Review.
• [Telomerase, cell immortality and cancer].
  Watanabe N. Watanabe N. Hokkaido Igaku Zasshi. 2001 May;76(3):127-32. Hokkaido Igaku Zasshi. 2001. PMID: 11481865 Review. Japanese.

Cited by

• Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
  Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, Chintakuntlawar AV, Pawlicki J, Sylvester AJ, McMullan T, Samuels R, Kim JJ, Weiner D, Boyer JD, Morrow MP, Humeau L, Skolnik JM. Vonderheide RH, et al. J Immunother Cancer. 2021 Jul;9(7):e003019. doi: 10.1136/jitc-2021-003019. J Immunother Cancer. 2021. PMID: 34230114 Free PMC article. Clinical Trial.
• HIV-1 induces telomerase activity in monocyte-derived macrophages, possibly safeguarding one of its reservoirs.
  Reynoso R, Wieser M, Ojeda D, Bönisch M, Kühnel H, Bolcic F, Quendler H, Grillari J, Grillari-Voglauer R, Quarleri J. Reynoso R, et al. J Virol. 2012 Oct;86(19):10327-37. doi: 10.1128/JVI.01495-12. Epub 2012 Jul 11. J Virol. 2012. PMID: 22787205 Free PMC article.
• Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model.
  Palanca-Wessels MC, Klingelhutz A, Reid BJ, Norwood TH, Opheim KE, Paulson TG, Feng Z, Rabinovitch PS. Palanca-Wessels MC, et al. Carcinogenesis. 2003 Jul;24(7):1183-90. doi: 10.1093/carcin/bgg076. Epub 2003 May 9. Carcinogenesis. 2003. PMID: 12807723 Free PMC article.
• Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.
  Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK. Shammas MA, et al. Clin Cancer Res. 2008 Aug 1;14(15):4971-80. doi: 10.1158/1078-0432.CCR-08-0473. Clin Cancer Res. 2008. PMID: 18676772 Free PMC article.
• A second chance for telomerase reverse transcriptase in anticancer immunotherapy.
  Zanetti M. Zanetti M. Nat Rev Clin Oncol. 2017 Feb;14(2):115-128. doi: 10.1038/nrclinonc.2016.67. Epub 2016 Jun 1. Nat Rev Clin Oncol. 2017. PMID: 27245281 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer